MCID: GLL008
MIFTS: 65

Gilles De La Tourette Syndrome malady

Categories: Genetic diseases, Rare diseases, Fetal diseases

Aliases & Classifications for Gilles De La Tourette Syndrome

About this section

Aliases & Descriptions for Gilles De La Tourette Syndrome:

Name: Gilles De La Tourette Syndrome 49 10 21 22 23 12 67 65
Tourette Syndrome 49 10 11 21 45 22 23 46 47 36 35 2
Tourette Disorder 21 45 22 23
Gilles De La Tourette's Syndrome 45 22 23
Tourette's Disease 23 24
Maladie De Tics 21 22
Gts 23 67
Chronic Motor and Vocal Tic Disorder 23
Gilles De La Tourette's Disease 22
 
Growing Teratoma Syndrome 65
Motor-Verbal Tic Disorder 10
Tourette's Disorder 22
Tourette's Syndrome 45
Psychogenic Tics 10
Guinon's Disease 10
Td 23
Ts 23

Characteristics:

HPO:

61
gilles de la tourette syndrome:
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 137580
Disease Ontology10 DOID:11119
ICD1027 F95.2
ICD9CM29 307.23
MeSH36 D005879
NCIt42 C35078
UMLS65 C0040517, C3891714

Summaries for Gilles De La Tourette Syndrome

About this section
NIH Rare Diseases:45 Tourette syndrome is a complex neurological disorder that is characterized by repetitive, sudden, uncontrolled (involuntary) movements and sounds (vocalizations) called tics. tourette syndrome is named for georges gilles de la tourette, who first described this disorder in 1885. a variety of genetic and environmental factors likely play a role in causing tourette syndrome. a small number of people with tourette syndrome have been found to have mutations involving the slitrk1 gene. the syndrome is believed to be linked to problems in certain areas of the brain, and the chemical substances (dopamine, serotonin, and norepinephrine) that help nerve cells talk to one another. it is estimated that about 1% of the population has tourette syndrome. many people with very mild tics may not be aware of them and never seek medical help. tourette syndrome is four times as likely to occur in boys as in girls. although tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the condition experience their worst symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood. last updated: 3/6/2016

MalaCards based summary: Gilles De La Tourette Syndrome, also known as tourette syndrome, is related to echolalia and schizophrenia, and has symptoms including stereotypic behavior, neurological speech impairment and attention deficit hyperactivity disorder. An important gene associated with Gilles De La Tourette Syndrome is SLITRK1 (SLIT And NTRK Like Family Member 1), and among its related pathways are Neurotransmitter Clearance In The Synaptic Cleft and Biogenic Amine Synthesis. The drugs risperidone and perphenazine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and prostate, and related mouse phenotypes are homeostasis/metabolism and behavior/neurological.

Disease Ontology:10 A tic disorder that is characterized by multiple physical (motor) tics and at least one vocal (phonic) tic present for more than a year.

UniProtKB/Swiss-Prot:67 Gilles de la Tourette syndrome: Neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities.

MedlinePlus:35 If you have tourette syndrome, you make unusual movements or sounds, called tics. you have little or no control over them. common tics are throat-clearing and blinking. you may repeat words, spin, or, rarely, blurt out swear words. tourette syndrome is a disorder of the nervous system. it often occurs with other problems, such as attention deficit hyperactivity disorder (adhd) obsessive-compulsive disorder (ocd) anxiety depression the cause of tourette syndrome is unknown. it is more common in boys than girls. the tics usually start in childhood and may be worst in the early teens. many people eventually outgrow them. no treatment is needed unless the tics interfere with everyday life. excitement or worry can make tics worse. calm, focused activities may make them better. medicines and talk therapy may also help. nih: national institute of neurological disorders and stroke

CDC:2 Comprehensive Behavioral Intervention for Tics (CBIT) is a promising new treatment to reduce tic symptoms.

NINDS:46 Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The first symptoms of TS are almost always noticed in childhood. Some of the more common tics include eye blinking and other vision irregularities, facial grimacing, shoulder shrugging, and head or shoulder jerking. Perhaps the most dramatic and disabling tics are those that result in self-harm such as punching oneself in the face, or vocal tics including coprolalia (uttering swear words) or echolalia (repeating the words or phrases of others). Many with TS experience additional neurobehavioral problems including inattention, hyperactivity and impulsivity, and obsessive-compulsive symptoms such as intrusive thoughts/worries and repetitive behaviors.

Genetics Home Reference:23 Tourette syndrome is a complex disorder characterized by repetitive, sudden, and involuntary movements or noises called tics. Tics usually appear in childhood, and their severity varies over time. In most cases, tics become milder and less frequent in late adolescence and adulthood.

OMIM:49 Tourette syndrome is a neurobehavioral disorder manifest particularly by motor and vocal tics and associated with... (137580) more...

Wikipedia:68 Tourette syndrome (also called Tourette\'s syndrome, Tourette\'s disorder, Gilles de la Tourette... more...

GeneReviews summary for NBK21138

Related Diseases for Gilles De La Tourette Syndrome

About this section

Diseases related to Gilles De La Tourette Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 112)
idRelated DiseaseScoreTop Affiliating Genes
1echolalia31.3CNTNAP2, DRD2
2schizophrenia28.8ADRA1A, ADRA2A, CNTNAP2, COMT, DBH, DRD2
3low gamma-gt familial intrahepatic cholestasis12.1
4glanzmann thrombasthenia11.6
5turner syndrome11.2
6tuberous sclerosis-111.0
7timothy syndrome11.0
8cholestasis, progressive familial intrahepatic 110.9
9cholestasis, benign recurrent intrahepatic10.9
10tsc2 angiomyolipomas, renal, modifier of10.9
11huriez syndrome10.9
12virus-associated trichodysplasia spinulosa10.9
13temperature-sensitive oculocutaneous albinism type 110.9
14pituitary deficiency due to empty sella turcica syndrome10.8ADRA1A, ADRA2A
15glucose metabolism disease10.8CNTNAP2, SLC6A3
16breast osteosarcoma10.7DRD2, DRD4
17kluver-bucy syndrome10.7DRD2, SLC6A3
18paranoid personality disorder10.7DRD2, DRD4, SLITRK1
19ainhum10.7COMT, DRD2
20long qt syndrome-1110.7DRD2, SGCE
21prostate adenocarcinoma10.7DRD2, SLC6A3
22kleptomania10.7DRD2, DRD4, SLC6A3
23specific language impairment10.7CNTNAP2, DRD2, SLC6A3
24testicular leydig cell tumor10.7DRD2, SLC6A3
25hallucinogen dependence10.7DRD2, DRD4, SLC6A3
26idiopathic peripheral autonomic neuropathy10.7ADRA1A, ADRA2A
27respiratory syncytial virus infectious disease10.7
28pandas10.6
29perrault syndrome10.6COMT, DRD4, SLC6A3
30maxillary sinus schneiderian papilloma10.6DBH, DRD2, SLC6A3
31intracranial aneurysm10.6COMT, DRD2, SLC6A3
32heroin dependence10.6DBH, DRD2, SLC6A3
33obsessive-compulsive disorder10.6
34polycystic kidney disease 210.6DBH, DRD2, SLC6A3
35viral exanthem10.6COMT, DRD2, SLC6A3
36arrhythmogenic right ventricular cardiomyopathy10.6BTBD9, DRD2, SLC6A3
37tic disorder10.6
38parkinsonism-dystonia, infantile10.6COMT, DRD2, SLC6A3
39encephalomalacia10.5COMT, DRD2, SLC6A3
40tarlov cysts10.5COMT, DRD2
41hemifacial spasm10.5COMT, DRD2, SLC6A3
42central nervous system hereditary degenerative disease10.5DRD2, SGCE, SLC6A3
43hyperglobulinemic purpura10.5COMT, DRD2, DRD4
44multifocal dystonia10.5DRD2, DRD5, SGCE
45chronic gonorrhea of cervix10.5COMT, DRD2, DRD4, SLC6A3
46trichotillomania10.5
47candidiasis10.5COMT, DRD2, DRD4, SLC6A3
48drug dependence10.4DRD2, DRD4, DRD5, SLC6A3
49zebra body myopathy10.4COMT, DBH, DRD2, DRD4
50chronic tic disorder10.4

Graphical network of the top 20 diseases related to Gilles De La Tourette Syndrome:



Diseases related to gilles de la tourette syndrome

Symptoms for Gilles De La Tourette Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

137580

Clinical features from OMIM:

137580

HPO human phenotypes related to Gilles De La Tourette Syndrome:

(show all 19)
id Description Frequency HPO Source Accession
1 stereotypic behavior typical (50%) HP:0000733
2 neurological speech impairment typical (50%) HP:0002167
3 attention deficit hyperactivity disorder typical (50%) HP:0007018
4 autism occasional (7.5%) HP:0000717
5 obsessive-compulsive behavior occasional (7.5%) HP:0000722
6 chorea occasional (7.5%) HP:0002072
7 migraine occasional (7.5%) HP:0002076
8 incoordination occasional (7.5%) HP:0002311
9 sleep disturbance occasional (7.5%) HP:0002360
10 neoplasm of the nervous system occasional (7.5%) HP:0004375
11 self-injurious behavior occasional (7.5%) HP:0100716
12 phonic tics HP:0100035
13 motor tics HP:0100034
14 echolalia HP:0010529
15 attention deficit hyperactivity disorder HP:0007018
16 sleep disturbance HP:0002360
17 self-mutilation HP:0000742
18 obsessive-compulsive behavior HP:0000722
19 aggressive behavior HP:0000718

UMLS symptoms related to Gilles De La Tourette Syndrome:


sleeplessness, stammering/stuttering/tic, vertigo/dizziness, hyperexplexia, chronic pain, tremor, syncope, sleep disturbances, seizures, sciatica, pain, headache, back pain, athetosis

Drugs & Therapeutics for Gilles De La Tourette Syndrome

About this section

Drugs for Gilles De La Tourette Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 130)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 3, Phase 1, Phase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
ClonidineapprovedPhase 41894205-90-72803
Synonyms:
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI)
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2,6-dichloro-N-(2-imidazolidinylidene)aniline
2,6-dichloro-N-2-imidazolidinylidenebenzenamide
2,6-dichloro-N-imidazolidin-2-ylideneaniline
2-((2,6-Dichlorophenyl)imino)imidazolidine
2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2)
2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichlorophenylamino)-2-imidazoline
2-(2,6-Dichlorophenylimino)imidazolidine
2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI)
2-[(2,6-Dichlorophenyl)imino]imidazoline
2-[(2,6-dichlorophenyl)imino]-2-imidazoline
4205-90-7
4205-91-8 (mono-hydrochloride)
57066-25-8
734571A
AB00514634
AC1L1EI5
AC1Q3K6V
AKOS001595470
Adesipress
BIDD:GT0547
BPBio1_000040
BRD-K98530306-001-02-1
BRD-K98530306-003-05-0
BSPBio_000036
BSPBio_001588
BSPBio_002055
Bio1_000470
Bio1_000959
Bio1_001448
Bio2_000308
Bio2_000788
C9H9Cl2N3
CAS-4205-91-8
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
CCRIS 7787
CHEBI:3757
CHEBI:46632
CHEMBL134
CID2803
Catapres
Catapres- TTS
Catapres-TTS
Catapresan
Catapressan
Catarpres
Catarpres-TTS
Catarpres-TTS (TN)
Catarpresan
Chlofazoline
Chlornidinum
Clofenil
Clonidin
Clonidina
Clonidina [INN-Spanish]
Clonidine
Clonidine (JAN/USAN/INN)
Clonidine HCl
Clonidine Hydrochloride
Clonidine Transdermal System
Clonidine [USAN:BAN:INN]
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
D00281
DB00575
DB07566
DivK1c_000774
 
Dixarit
Duraclon
Duraclont
EINECS 224-119-4
Gemiton
HMS1361P10
HMS1791P10
HMS1989P10
HMS2089G11
HSDB 3040
Hemiton
IDI1_000774
IDI1_034058
Ipotensium
Isoglaucon
KBio1_000774
KBio2_000308
KBio2_001821
KBio2_002876
KBio2_004389
KBio2_005444
KBio2_006957
KBio3_000615
KBio3_000616
KBio3_001275
KBioGR_000308
KBioGR_001572
KBioSS_000308
KBioSS_001821
Kapvay
Klofelin
Klofenil
L000193
LS-79606
Lopac-C-7897
Lopac0_000268
M 5041T
M-5041T
MolPort-001-779-668
MolPort-005-932-374
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
NCGC00015268-01
NCGC00015268-02
NCGC00015268-08
NCGC00024734-01
NCGC00024734-02
NCGC00024734-03
NCGC00024734-04
NCGC00024734-05
NCGC00179680-01
NINDS_000774
Nexiclon
Nexiclon Xr
Prestwick0_000248
Prestwick1_000248
Prestwick2_000248
Prestwick3_000248
SKF 34427
SPBio_001233
SPBio_002255
ST 155BS
ST-155-BS
ST-155BS
Spectrum2_001187
Spectrum3_000358
Spectrum4_000956
Spectrum5_000759
Spectrum_001341
T171
Tenso-Timelets
Tocris-0690
UNII-MN3L5RMN02
ZINC00896484
clonidine
nchembio.79-comp11
nchembio705-10
3
Aripiprazoleapproved, investigationalPhase 4, Phase 3342129722-12-960795
Synonyms:
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
Abilify
Abilify (TN)
Abilify DISCMELT
Abilify Discmelt
Abilify Maintena
Abilitat
Aripiprazol
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
Aripiprazolum
Aripirazole
Arpizol
Asprito|
BMS-337039
Bio-0004
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
CHEMBL1112
CID60795
 
CPD000466383
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
OPC 31
OPC-14597
OPC-31
Opc 14597
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
aripiprazol
aripiprazole
aripiprazolum
||OPC 14597
4
Fluvoxamineapproved, investigationalPhase 44654739-18-33404, 5324346
Synonyms:
(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime
2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
54739-18-3
61718-82-9 (maleate)
AB00514702
AC-1679
AC1NT50J
AC1Q4JNU
AR-1D5360
BIDD:GT0609
BPBio1_001199
BRD-K53517854-050-03-2
BSPBio_001089
C07571
C15H21F3N2O2
CHEBI:5138
CHEMBL814
CID5324346
D07984
DB00176
Dumirox
Dumyrox
Faverin
 
Fevarin
Floxyfral
Fluvoxamina
Fluvoxamina [INN-Spanish]
Fluvoxamine
Fluvoxamine (INN)
Fluvoxamine Maleate
Fluvoxamine [INN:BAN]
Fluvoxamine maleate
Fluvoxamine-CR
Fluvoxaminum
Fluvoxaminum [INN-Latin]
I01-8382
LS-101999
Lopac0_000495
Luvox
Maveral
MolPort-005-943-374
NCGC00018193-07
NCGC00021870-04
NCGC00021870-05
Prestwick2_000995
Prestwick3_000995
UNII-O4L1XPO44W
fluvoxamine
fluvoxamine-CR
5
HaloperidolapprovedPhase 413652-86-83559
Synonyms:
1-(3-P-Fluorobenzoylpropyl)-4-P-chlorophenyl-4-hydroxypiperidine
4'-Fluoro-4-(4-(P-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
4-(4-(Para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
5-21-02-00377 (Beilstein Handbook Reference)
52-86-8
AB00052008
AC-19691
AC1L1G7K
AC1Q77Z0
AKOS000280660
ALDO
Aldo
Aloperidin
Aloperidol
Aloperidolo
Aloperidolo [DCIT]
Aloperidolo [Italian]
Aloperidon
Apo-Haloperidol
BIDD:GT0128
BPBio1_000144
BPBio1_001231
BRD-K67783091-001-04-8
BRD-K67783091-001-05-5
BRN 0331267
BSPBio_000130
BSPBio_002096
Bio-0705
Biomol-NT_000035
Bioperidolo
Brotopon
C01814
C21H23ClFNO2
CAS-52-86-8
CCRIS 1630
CHEBI:5613
CHEMBL54
CID3559
D00136
D006220
DB00502
DivK1c_000654
Dozic
Dozix
EINECS 200-155-6
EU-0100583
Einalon S
Eukystol
Fortunan
Galoperidol
H 1512
H0912
H1512_SIGMA
HMS1568G12
HMS1920D03
HMS2089M15
HMS2091J09
HMS502A16
HSDB 3093
Haldol
Haldol Decanoate
Haldol La
Haldol Solutab
Halidol
Halojust
Halol
Halopal
Haloperido
Haloperidol
Haloperidol (JP15/USP)
Haloperidol (JP15/USP/INN)
Haloperidol Decanoate
Haloperidol Intensol
Haloperidol Lactate
Haloperidol [USAN:INN:BAN:JAN]
Haloperidolum
Haloperidolum [INN-Latin]
Halopidol
Halopoidol
Halosten
I14-13404
I14-14165
 
IDI1_000654
KBio1_000654
KBio2_001341
KBio2_002390
KBio2_003909
KBio2_004958
KBio2_006477
KBio2_007526
KBio3_001316
KBio3_002869
KBioGR_000980
KBioGR_002390
KBioSS_001341
KBioSS_002395
Keselan
L000288
LS-48311
Lealgin Compositum
Lealgin compositum
Linton
Lopac-H-1512
Lopac0_000583
MLS000028450
MLS001146904
McN-JR-1625
Mixidol
MolPort-000-883-311
NCGC00015500-01
NCGC00015500-02
NCGC00015500-06
NCGC00015500-14
NCGC00016234-01
NCGC00023875-02
NCGC00023875-04
NCGC00023875-05
NCGC00023875-06
NCGC00023875-07
NCGC00023875-08
NCGC00023875-09
NINDS_000654
NSC 170973
NSC 615296
NSC170973
NSC615296
Novo-Peridol
Oprea1_509923
Pekuces
Peluces
Peridol
Pernox
Pms Haloperidol
Prestwick0_000115
Prestwick1_000115
Prestwick2_000115
Prestwick3_000115
Prestwick_250
Probes1_000255
Probes2_000296
QTL1_000042
R 1625
R-1625
S1920_Selleck
SMR000058303
SPBio_001236
SPBio_002069
SPECTRUM1500325
Serenace
Serenase
Serenelfi
Sernas
Sernel
Sigaperidol
Spectrum2_001268
Spectrum3_000448
Spectrum4_000570
Spectrum5_000788
Spectrum_000861
Tocris-0931
UNII-J6292F8L3D
Ulcolind
Uliolind
Vesalium
WLN: T6NTJ A3VR DF& DQ DR DG
cMAP_000037
gamma-(4-(P-Chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
haloperidol
6
Guanfacineapproved, investigationalPhase 4, Phase 35329110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine
Guanfacine (INN)
Guanfacine Hydrochloride
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tenex
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
7
Olanzapineapproved, investigationalPhase 4379132539-06-14585
Synonyms:
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC-665
AC1L1IHS
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
LS-152313
LY 170053
LY-170052
LY-170053
 
Lanzac
Lilly brand of olanzapine
MLS000759457
MLS001165781
MLS001195646
MLS001424057
Midax
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
Olanzapina
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapine pamoate
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
olanzapina
olanzapine
olanzapinum
8
Riluzoleapproved, investigationalPhase 4591744-22-55070
Synonyms:
1744-22-5
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-amino-6-trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC-730
AC1L1JJL
AC1Q530H
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
BB_SC-4839
BF-37
BIDD:GT0055
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
LS-40688
 
Lopac-R-116
Lopac0_001064
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick-03A08
Prestwick0_000167
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
RP 54274
RP-54274
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole HCl
Riluzole Hydrochloride
Riluzole [USAN:INN]
Riluzolum
Riluzolum [INN-Latin]
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
STK503686
Spectrum2_000550
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
riluzole
9
FluoxetineapprovedPhase 422954910-89-33386
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
AKOS003663021
Adofen
Animex-On
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
Bio-0787
Biomol-NT_000152
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
Fluoxetine
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine Hcl
Fluoxetine Hydrochloride
Fluoxetine [USAN:INN:BAN]
Fluoxetinum
 
Fluoxetinum [INN-Latin]
Fluoxétine
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
LS-31040
Lilly-110140
Lopac0_000558
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
SPBio_001815
SPBio_002382
STK734483
Sarafem
SpecPlus_000723
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
Spectrum_001679
TL8003595
UNII-01K63SUP8D
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
fluoxetine
fluoxetine (Prozac)
nchembio.534-comp2
10
GalantamineapprovedPhase 4103357-70-09651, 908828, 908828, 9651
Synonyms:
(-)-Galanthamine
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
1551-02-6
1953-04-4
1dx6
1qti
357-70-0
4-27-00-02184 (Beilstein Handbook Reference)
736-79-8
AC-20240
AC1L1TIM
BIDD:GT0517
BPBio1_000480
BRD-K49481516-004-03-5
BRD-K49481516-004-04-3
BRN 0093736
BSPBio_000436
BSPBio_003416
C08526
CHEBI:42944
CHEMBL659
CID9651
D04292
DivK1c_000590
GNT
Galantamin
Galantamina
Galantamina [INN-Spanish]
Galantamine
Galantamine (USAN/INN)
Galantamine Hydrobromide
Galantamine [USAN:INN]
Galantamine hydrobromide
Galantaminum
Galantaminum [INN-Latin]
Galanthamine
Galanthamine hydrobromide
Galanthaminum
 
HMS2089H03
HSDB 7361
IDI1_000590
InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
Jilkon
KBio1_000590
KBio2_001751
KBio2_004319
KBio2_006887
KBio3_002636
KBioGR_001417
KBioSS_001751
LS-71039
Lycoremin
Lycoremine
MolPort-002-521-885
NCGC00024731-02
NINDS_000590
NSC 100058
Prestwick0_000588
Prestwick1_000588
Prestwick2_000588
Prestwick3_000588
Probes1_000055
Probes2_000395
Razadyne
Razadyne ER
Reminyl
Reminyl (TN)
SDCCGMLS-0066737.P001
SMP1_000131
SPBio_002655
STOCK1N-46108
Spectrum3_001738
Spectrum4_000839
Spectrum5_001673
Spectrum_001271
UNII-0D3Q044KCA
galanthamine
11Dopamine AgentsPhase 4, Phase 3, Phase 1, Phase 23084
12Dopamine AntagonistsPhase 4, Phase 3, Phase 1, Phase 2927
13Neuroprotective AgentsPhase 4, Phase 31376
14Gastrointestinal AgentsPhase 46401
15Cytochrome P-450 Enzyme InhibitorsPhase 43036
16AntiemeticsPhase 43213
17Cytochrome P-450 CYP2D6 InhibitorsPhase 4602
18Excitatory Amino AcidsPhase 41109
19Haloperidol decanoatePhase 4136
20Excitatory Amino Acid AgonistsPhase 417
21AnticonvulsantsPhase 4, Phase 3, Phase 1, Phase 22249
22Serotonin Uptake InhibitorsPhase 41369
23Serotonin AgentsPhase 4, Phase 22668
24Excitatory Amino Acid AntagonistsPhase 41095
25
SerotoninPhase 4, Phase 2314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
26Antidepressive Agents, Second-GenerationPhase 41087
27Neurotransmitter Uptake InhibitorsPhase 4, Phase 22857
28Adrenergic AgentsPhase 4, Phase 3, Phase 24204
29Adrenergic AgonistsPhase 4, Phase 32331
30Adrenergic alpha-2 Receptor AgonistsPhase 4, Phase 3790
31Tranquilizing AgentsPhase 4, Phase 3, Phase 1, Phase 23597
32Psychotropic DrugsPhase 4, Phase 3, Phase 1, Phase 25501
33Antipsychotic AgentsPhase 4, Phase 3, Phase 1, Phase 22130
34Antidepressive AgentsPhase 42367
35Central Nervous System DepressantsPhase 4, Phase 3, Phase 1, Phase 210016
36Adrenergic alpha-AgonistsPhase 4, Phase 31300
37Protective AgentsPhase 4, Phase 3, Phase 25651
38Neurotransmitter AgentsPhase 4, Phase 3, Phase 1, Phase 214795
39EtiracetamPhase 4196
40Antihypertensive AgentsPhase 4, Phase 33618
41PiracetamPhase 41367491-74-9
42AnalgesicsPhase 49358
43Peripheral Nervous System AgentsPhase 418510
44Nootropic AgentsPhase 4604
45Cholinergic AgentsPhase 43243
46Cholinesterase InhibitorsPhase 4498
47serineNutraceuticalPhase 4770
48Glutamic AcidNutraceuticalPhase 4201
49TryptophanNutraceuticalPhase 454
50
TopiramateapprovedPhase 324097240-79-45284627
Synonyms:
-D-fructopyranose deriv.
.beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI)
2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di- O -isopropylidene-(beta)-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.
97240-79-4
AKOS000424547
BIDD:GT0854
BIDD:PXR0127
BRN 5988957
BSPBio_002306
C052342
C07502
C12H21NO8S
CBChromo1_000352
CHEBI:129573
CHEMBL220492
CID5284627
CPD000466325
Cilag brand of topiramate
D00537
DB00273
Epitoma
Epitomax
HMS1922H06
HMS2051L09
HMS2093D20
HSDB 7531
Janssen brand of topiramate
KS-1122
KW-6485
LS-187392
LS-69764
MLS000759431
MLS001424070
McN 4853
McN-4853
MolPort-001-615-062
MolPort-002-885-869
NCGC00178714-01
Ortho brand of topiramate
 
Qudexy XR
RWJ 17021
RWJ-17021
RWJ-17021-000
S1438_Selleck
SAM001246601
SMR000466325
SPBio_000995
SPECTRUM1505801
STOCK1N-71037
Spectrum2_001128
T0575_SIGMA
TL8006021
TOR
TPM
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Topamac
Topamax
Topamax (TN)
Topamax Sprinkle
Topamax, Topiramate
Topimax
Topina
Topiramate
Topiramate (JAN/USAN/INN)
Topiramate (TPM)
Topiramate / Placebo
Topiramate [USAN:BAN:INN]
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
Trokendi Xr
UNII-0H73WJJ391
USL-255
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate
topiramate
topiramate tablet
topiramatum [Latin]

Interventional clinical trials:

(show top 50)    (show all 119)
idNameStatusNCT IDPhase
1Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic NeurotransmissionCompletedNCT01018056Phase 4
2Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT00241176Phase 4
3Comparison of Keppra and Clonidine in the Treatment of TicsCompletedNCT00370838Phase 4
4Treatment of Obsessive-Compulsive DisorderCompletedNCT00000373Phase 4
5Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHDRecruitingNCT00152750Phase 4
6Guanfacine in Children With Tic DisordersActive, not recruitingNCT01547000Phase 4
7Safety Study of Galantamine in Tic DisordersTerminatedNCT00226824Phase 4
8Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01727713Phase 3
9Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01727700Phase 3
10A Randomized, Placebo-Controlled, Tourette Syndrome Study.CompletedNCT00206323Phase 3
11An Open-Label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.CompletedNCT00206336Phase 3
12Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity DisorderCompletedNCT00004376Phase 3
13Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's DisorderCompletedNCT00706589Phase 3
14Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01416441Phase 3
15Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01418352Phase 3
16Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01418339Phase 3
17Phase III Study of 5LGr to Treat Tic DisorderCompletedNCT01501695Phase 3
18Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in ChildrenCompletedNCT00218777Phase 2, Phase 3
19Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)CompletedNCT00001768Phase 3
20Pallidal Stimulation and Gilles de la Tourette SyndromeActive, not recruitingNCT00478842Phase 3
21Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette SyndromeTerminatedNCT00681863Phase 3
22Subthalamic Stimulation in Tourette's SyndromeCompletedNCT02619084Phase 2
23Thalamic Deep Brain Stimulation for Tourette SyndromeCompletedNCT00311909Phase 2
24VoIP Delivered Behavior Therapy for Tourette SyndromeCompletedNCT02247206Phase 2
25N-acetylcysteine (NAC) for Children With Tourette SyndromeCompletedNCT01172288Phase 2
26A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette SyndromeCompletedNCT02217007Phase 2
27Ecopipam Treatment of Tourette SyndromeCompletedNCT01244633Phase 1, Phase 2
28Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic DisorderCompletedNCT00231985Phase 2
29Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's SyndromeCompletedNCT00529308Phase 2
30A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette SyndromeCompletedNCT01647269Phase 2
31Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette SyndromeCompletedNCT00004393Phase 2
32Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette SyndromeCompletedNCT00004652Phase 2
33Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's DisorderCompletedNCT01904773Phase 2
34Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's DisorderCompletedNCT01585207Phase 1, Phase 2
35Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV CriteriaCompletedNCT00558467Phase 2
36Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's SyndromeRecruitingNCT02112253Phase 1, Phase 2
37Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 YearsRecruitingNCT02102698Phase 2
38Safety and Efficacy Study of NBI-98854 in Adults With Tourette SyndromeRecruitingNCT02581865Phase 2
39Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette SyndromeRecruitingNCT02679079Phase 2
40Cannabis for Inflammatory Bowel DiseaseRecruitingNCT01040910Phase 1, Phase 2
41FAAH Inhibitor Trial for Adults With Tourette SyndromeSuspendedNCT02134080Phase 2
42Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's SyndromeTerminatedNCT01475383Phase 2
43Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette SyndromeTerminatedNCT01043549Phase 2
44A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's SyndromeWithdrawnNCT01133353Phase 2
45Developing Cognitive Training for Tourette SyndromeCompletedNCT01440023Phase 1
46A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)CompletedNCT02674321Phase 1
47High Frequency Stimulation of the GPi or Thalamus in Tourette's SyndromeCompletedNCT00139308Phase 1
48Open-Trial of EPI-743 for Adults With Tourette SyndromeCompletedNCT01719523Phase 1
49Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette SyndromeCompletedNCT02256475Phase 1
50Transcranial Magnetic Stimulation for Children With Tourette's SyndromeRecruitingNCT02356003Phase 1

Search NIH Clinical Center for Gilles De La Tourette Syndrome

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: tourette syndrome

Genetic Tests for Gilles De La Tourette Syndrome

About this section

Genetic tests related to Gilles De La Tourette Syndrome:

id Genetic test Affiliating Genes
1 Tourette Syndrome22 SLITRK1

Anatomical Context for Gilles De La Tourette Syndrome

About this section

MalaCards organs/tissues related to Gilles De La Tourette Syndrome:

33
Brain, Eye, Prostate, Pituitary, Colon, T cells, Cortex

Animal Models for Gilles De La Tourette Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Gilles De La Tourette Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053767.6ADRA1A, ADRA2A, BTBD9, COMT, DBH, DRD2
2MP:00053866.9ADRA1A, ADRA2A, BTBD9, CNTNAP2, COMT, DBH
3MP:00036316.5ADRA2A, BTBD9, CNTNAP2, COMT, DBH, DPP6

Publications for Gilles De La Tourette Syndrome

About this section

Articles related to Gilles De La Tourette Syndrome:

(show top 50)    (show all 344)
idTitleAuthorsYear
1
Impact of Perceived Stress, Anxiety-Depression and Social Support on Coping Strategies of Parents Having A Child With Gilles de la Tourette Syndrome. (26804511)
2016
2
The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review. (26880181)
2016
3
Retraction Note to: Association of Catechol-O-methyltransferase val/met polymorphism with cognitive function in Gilles de la Tourette syndrome patients. (26282617)
2015
4
Gilles de la Tourette syndrome is not linked to contactin-associated protein receptor 2 antibodies. (26462472)
2015
5
Temporary deep brain stimulation in Gilles de la Tourette syndrome: A feasible approach? (26290773)
2015
6
Cerebellar neurophysiology in Gilles de la Tourette syndrome and its role as a target for therapeutic intervention. (26643291)
2015
7
Association of ADORA1 rs2228079 and ADORA2A rs5751876 Polymorphisms with Gilles de la Tourette Syndrome in the Polish Population. (26317759)
2015
8
The psychopathological spectrum of Gilles de la Tourette syndrome. (23131314)
2013
9
The pathophysiology of echopraxia/echolalia: relevance to Gilles de la Tourette syndrome. (22807284)
2012
10
Echoes from childhood--imitation in Gilles de la Tourette Syndrome. (22278950)
2012
11
Delayed experience of volition in Gilles de la Tourette syndrome. (21212106)
2011
12
"Trousseau's disease:" a description of the Gilles de la Tourette syndrome 12 years before 1885. (20672342)
2010
13
Imitation in patients with Gilles de la Tourette syndrome--a behavioral study. (20535824)
2010
14
Neurosurgical treatment for Gilles de la Tourette syndrome: the Italian perspective. (19913662)
2009
15
The behavioral spectrum of Gilles de la Tourette syndrome. (19359447)
2009
16
The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 2: tentative explanations for differing prevalence figures in GTS, including the possible effects of psychopathology, aetiology, cultural differences, and differing phenotypes. (18940378)
2008
17
Analysis of the dopamine beta hydroxylase gene in Gilles de la Tourette syndrome. (16838359)
2006
18
Perceptual-motor skill learning in Gilles de la Tourette syndrome. Evidence for multiple procedural learning and memory systems. (15989936)
2005
19
Serotonin receptor genes HTR3A and HTR3B are not involved in Gilles de la Tourette syndrome. (16314763)
2005
20
Indications of linkage and association of Gilles de la Tourette syndrome in two independent family samples: 17q25 is a putative susceptibility region. (15303240)
2004
21
Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotype. (12682296)
2003
22
Obsessive-compulsive symptom dimensions in affected sibling pairs diagnosed with Gilles de la Tourette syndrome. (12497616)
2003
23
Further evidence for linkage of Gilles de la Tourette syndrome (GTS) susceptibility loci on chromosomes 2p11, 8q22 and 11q23-24 in South African Afrikaners. (11304830)
2001
24
Home alone: methods to maximize tic expression for objective videotape assessments in Gilles de la Tourette syndrome. (11481693)
2001
25
Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. (10705938)
2000
26
A perplexing document in the early history of Gilles de la Tourette Syndrome: Melotti's rendition of a "Lecture of Charcot" (including a complete translation from the Italian with commentary). (11624136)
1999
27
Genome scan for linkage to Gilles de la Tourette syndrome. (10402514)
1999
28
Gilles de la Tourette syndrome with schizophrenia and obsessive-compulsive disorder: a case report. (10570769)
1999
29
Gilles de la Tourette syndrome. (9749024)
1998
30
Obsessive compulsive symptoms in Gilles de la Tourette syndrome and obsessive compulsive disorder: differences by diagnosis and family history. (9259380)
1997
31
Investigation of the potential role of genetic imprinting in Gilles de la Tourette syndrome. (8030670)
1994
32
Coprolalia in younger patients with Gilles de la Tourette syndrome. (7845402)
1994
33
Blunted growth hormone response to clonidine in Gilles de la Tourette syndrome. (8047638)
1994
34
Can children with Gilles de la Tourette syndrome edit their intentions? (8208891)
1994
35
The metabolic effects of limbic leucotomy in Gilles de la Tourette syndrome. (8410025)
1993
36
Atypical presentation of Gilles de la Tourette syndrome. (1562883)
1992
37
Reflex tics in two patients with Gilles de la Tourette syndrome. (1790463)
1991
38
No evidence for genetic linkage of Gilles de la Tourette syndrome on chromosomes 7 and 18. (2395161)
1990
39
Management of Gilles de la Tourette syndrome using sulpiride. (2357704)
1990
40
The Gilles de la Tourette syndrome: the current status. (2673473)
1989
41
Psychopathology and movement disorders: a new perspective on the Gilles de la Tourette syndrome. (2666582)
1989
42
Detection of major gene for Gilles de la Tourette syndrome. (6587774)
1984
43
Serum haloperidol levels in Gilles de la Tourette syndrome. (6939449)
1981
44
Increased body movements during sleep in Gilles de la Tourette syndrome. (6942662)
1981
45
Noradrenergic and dopaminergic mechanisms in Gilles de la Tourette syndrome. (76814)
1978
46
Purine phosphoribosyltransferase in gilles de la Tourette syndrome. (299777)
1977
47
Gilles de la Tourette syndrome: a case study. (812017)
1975
48
Clinical dangers of psychological theorizing. The Gilles de la Tourette syndrome. (5291647)
1971
49
Haloperidol for the Gilles de la Tourette syndrome. (5262166)
1970
50
GILLES DE LA TOURETTE SYNDROME IN AN AUTISTIC CHILD. (14338424)
1965

Variations for Gilles De La Tourette Syndrome

About this section

Clinvar genetic disease variations for Gilles De La Tourette Syndrome:

5
id Gene Variation Type Significance SNP ID Assembly Location
1HDCNM_002112.3(HDC): c.951G> A (p.Trp317Ter)single nucleotide variantPathogenicrs267606861GRCh37Chr 15, 50544717: 50544717
2SLITRK1NM_052910.2(SLITRK1): c.1264delC (p.Leu422Phefs)deletionPathogenicrs193302861GRCh37Chr 13, 84454379: 84454379
3SLITRK1NM_052910.2(SLITRK1): c.*689G> Asingle nucleotide variantPathogenicrs191284403GRCh37Chr 13, 84452863: 84452863

Expression for genes affiliated with Gilles De La Tourette Syndrome

About this section
Search GEO for disease gene expression data for Gilles De La Tourette Syndrome.

Pathways for genes affiliated with Gilles De La Tourette Syndrome

About this section

GO Terms for genes affiliated with Gilles De La Tourette Syndrome

About this section

Cellular components related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1integral component of plasma membraneGO:00058879.6DRD2, DRD4, DRD5, SLC6A3
2dendriteGO:00304259.1CNTNAP2, COMT, DRD2, DRD4, SGCE
3integral component of membraneGO:00160218.2ADRA2A, CNTNAP2, COMT, DPP6, DRD4, DRD5

Biological processes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1modulation of synaptic transmissionGO:005080410.5DRD2, DRD4
2negative regulation of voltage-gated calcium channel activityGO:190138610.5DRD2, DRD4
3dopamine metabolic processGO:004241710.5COMT, DRD4
4dopamine catabolic processGO:004242010.5COMT, DBH
5negative regulation of insulin secretionGO:004667610.4ADRA2A, DRD2
6adenylate cyclase-activating adrenergic receptor signaling pathwayGO:007188010.4ADRA1A, DRD2
7adult locomotory behaviorGO:000834410.3BTBD9, DRD4
8catecholamine biosynthetic processGO:004242310.3DBH, HDC
9negative regulation of cAMP biosynthetic processGO:003081810.2ADRA2A, DRD4
10behavioral response to cocaineGO:004814810.1DRD2, DRD4
11phospholipase C-activating dopamine receptor signaling pathwayGO:006015810.0DRD2, DRD5
12response to amphetamineGO:00019759.9DBH, DRD2, DRD4
13synaptic transmission, dopaminergicGO:00019639.9DRD2, DRD5
14associative learningGO:00083069.8DRD2, DRD4
15response to drugGO:00424939.3ADRA1A, COMT, DRD2, SLC1A3, SLC6A3

Molecular functions related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dopamine bindingGO:003524010.0DRD5, SLC6A3

Sources for Gilles De La Tourette Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet